News Headlines Article

California lawmakers target $1,000 hepatitis pill, other costly drugs
Los Angeles Times

California lawmakers are joining the national debate over what effect high-priced specialty drugs are having on medical costs for consumers and taxpayers.

A hearing Wednesday led by state Sen. Ed Hernandez (D-West Covina) is expected to feature testimony from an executive at Gilead Sciences Inc. about Sovaldi, the company’s $1,000-per-pill hepatitis C drug that has drawn criticism from members of Congress, Medicaid officials and health insurers.